1
|
Boidart A, Darveau M, Déry N, Racine MC. Real-World Budget Impact of Listing a Biosimilar of Rituximab. Can J Hosp Pharm 2020; 73:13-18. [PMID: 32109956 PMCID: PMC7023921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
BACKGROUND The approval of new biosimilars by national health agencies is expected to generate significant cost savings for health care systems. This is particularly the case with the biosimilar of rituximab approved for the Canadian market in 2019. However, several uncertainties remain regarding utilization of this agent. OBJECTIVES To determine the proportion of total annual drug expenses for each indication for rituximab in the hospital setting and to determine potential savings related to introduction of a biosimilar. METHODS A budget impact analysis was performed through 3 real-world scenarios, based on data obtained from a large university teaching hospital for a 12-month period. RESULTS This study involved data for 420 patients. Annual expenses for rituximab for all indications represented 7.7% of total annual drug spending for the hospital, of which 5.0% was related specifically to indications approved by Health Canada. More than 6% of the annual drug expenses was attributable to the use of rituximab for oncologic indications, including 1.8% for uses not approved by Health Canada. Overall, each 10% reduction in the price of a biosimilar of rituximab (relative to the reference rituximab) would result in annual savings of about 0.8% of total drug expenses in the hospital if a biosimilar was used for all real-world indications, whether approved by Health Canada or not. CONCLUSIONS The introduction of a biosimilar of rituximab to the Canadian market would generate significant savings. To properly assess the potential savings that this agent could generate in the limited budget environment of a hospital, it seems important to consider all of the indications for which it could be used.
Collapse
Affiliation(s)
- Arnaud Boidart
- , MPharm, MBA, is with the Faculty of Pharmacy of Amiens, Amiens, France
| | - Martin Darveau
- , BPharm, MSc, is with the Pharmacy Department, Centre hospitalier universitaire de Québec-Université Laval, Québec, Quebec
| | - Nicole Déry
- , BPharm, MSc, is with the Pharmacy Department, Centre hospitalier universitaire de Québec-Université Laval, Québec, Quebec
| | - Marie-Claude Racine
- , BPharm, MSc, is with the Pharmacy Department, Centre hospitalier universitaire de Québec-Université Laval, Québec, Quebec
| |
Collapse
|
2
|
Zheng YH, Xu L, Cao C, Feng J, Tang HL, Shu MM, Gao GX, Chen XQ. Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis. Onco Targets Ther 2019; 12:2751-2766. [PMID: 31043792 PMCID: PMC6469478 DOI: 10.2147/ott.s191179] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background To evaluate the efficacy and safety of rituximab-based combination therapy for Waldenström macroglobulinemia (WM), we conducted this meta-analysis by pooling the rates of overall response, major response, complete response, and grade ≥3 hematological adverse events. Methods and materials We searched for relevant studies in the databases of PubMed, Web of Science, Embase, and the Cochrane Library. The qualitative assessment of all the included articles was conducted with reference to the Newcastle–Ottawa Scale. A random-effects model was selected to perform all pooled analyses. Results We identified altogether 22 studies with a total of 806 symptomatic WM patients enrolled. The pooled analysis indicated that the rituximab-based combination therapy achieved an overall response rate (ORR) of 84% (95% CI: 81%–87%), a major response rate (MRR) of 71% (95% CI: 66%–75%), and a complete response rate (CRR) of 7% (95% CI: 5%–10%). Rituximab plus conventional alkylating agents–containing chemotherapy (subgroup A) yielded an ORR of 86% (95% CI: 81%–89%), an MRR of 74% (95% CI: 69%–79%), and a CRR of 8% (95% CI: 4%–14%). Rituximab plus purine analog (subgroup B) resulted in an ORR of 85% (95% CI: 79%–89%), an MRR of 74% (95% CI: 66%–81%), and a CRR of 9% (95% CI: 4%–15%). Rituximab plus proteasome inhibitor (subgroup C) resulted in an ORR of 86% (95% CI: 81%–90%), an MRR of 68% (95% CI: 58%–77%), and a CRR of 7% (95% CI: 3%–11%). Rituximab plus immunomodulatory drug (subgroup D) attained relatively lower response rates, with an ORR of 67% (95% CI: 51%–81%), an MRR of 56% (95% CI: 27%–83%), and a CRR of 5% (95% CI: 1%–12%). Common grade ≥3 hematological adverse events consisted of neutropenia (33%, 95% CI: 17%–52%), thrombocytopenia (7%, 95% CI: 3%–11%), and anemia (5%, 95% CI: 3%–9%). Conclusion Rituximab in combination with an alkylating agent, purine analog, or proteasome inhibitor is highly effective with tolerable hematological toxicities for WM.
Collapse
Affiliation(s)
- Yan-Hua Zheng
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China, ;
| | - Li Xu
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China, ;
| | - Chun Cao
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China, ;
| | - Juan Feng
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China, ;
| | - Hai-Long Tang
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China, ;
| | - Mi-Mi Shu
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China, ;
| | - Guang-Xun Gao
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China, ;
| | - Xie-Qun Chen
- Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China, ;
| |
Collapse
|
3
|
Kastritis E, Dimopoulos MA. Proteasome Inhibitors in Waldenström Macroglobulinemia. Hematol Oncol Clin North Am 2018; 32:829-840. [PMID: 30190021 DOI: 10.1016/j.hoc.2018.05.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Waldenström macroglobulinemia (WM) remains an incurable B-cell lymphoproliferative disorder, yet therapy is only considered for patients with symptomatic disease. Primary therapy options for WM include combinations based on anti-CD20 monoclonal antibodies, mainly rituximab. However, proteasome inhibitors have become an important part of WM therapy both as primary therapy and as salvage option. Bortezomib is the proteasome inhibitor most studied and with extensive clinical experience, but new proteasome inhibitors (carfilzomib, ixazomib, oprozomib), with different toxicity profiles, routes of administration, and probably with preserved or improved activity, have become available and may also find their way into WM therapy.
Collapse
Affiliation(s)
- Efstathios Kastritis
- Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, 80 Vassilisis Sofias Avenue, Athens 11528, Greece.
| | - Meletios A Dimopoulos
- Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, 80 Vassilisis Sofias Avenue, Athens 11528, Greece
| |
Collapse
|
4
|
Aiello A, D’Ausilio A, Lo Muto R, Randon F, Laurenti L. Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy. JOURNAL OF MARKET ACCESS & HEALTH POLICY 2017; 5:1393308. [PMID: 29201288 PMCID: PMC5700492 DOI: 10.1080/20016689.2017.1393308] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Accepted: 10/10/2017] [Indexed: 06/07/2023]
Abstract
Background and Objective: Ibrutinib has recently been approved in Europe for Waldenström Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the incremental cost-effectiveness ratio (ICER) of ibrutinib in relapse/refractory WM, compared with the Italian current therapeutic pathways (CTP). Methods: A Markov model was adapted for Italy considering the National Health System perspective. Input data from literature as well as global trials were used. The percentage use of therapies, and healthcare resources consumption were estimated according to expert panel advice. Drugs ex-factory prices and national tariffs were used for estimating costs. The model had a 15-year time horizon, with a 3.0% discount rate for both clinical and economic data. Deterministic and probabilistic sensitivity analyses were performed to test the results strength. Results: Ibrutinib resulted in increased Life Years Gained (LYGs) and increased costs compared to CTP, with an ICER of €52,698/LYG. Sensitivity analyses confirmed the results of the BaseCase. Specifically, in the probabilistic analysis, at a willingness to pay threshold of €60,000/LYG ibrutinib was cost-effective in 84% of simulations. Conclusions: Ibrutinib has demonstrated a positive cost-effectiveness profile in Italy.
Collapse
Affiliation(s)
- Andrea Aiello
- Price and Market Access Department, Creativ – Ceutical, Milan, Italy
| | - Anna D’Ausilio
- Price and Market Access Department, Creativ – Ceutical, Milan, Italy
| | - Roberta Lo Muto
- Health Economics Market Access Reimbursement Department, Janssen-Cilag, Cologno Monzese, Italy
| | - Francesca Randon
- Health Economics Market Access Reimbursement Department, Janssen-Cilag, Cologno Monzese, Italy
| | - Luca Laurenti
- Department of Hematology, Catholic University of Rome, “A. Gemelli” Hospital, Rome, Italy
| |
Collapse
|